Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Correction to: Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis.

Pohjankoski H, Kautiainen H, Lauri JV, Puolakka K, Rantalaiho V.

Clin Rheumatol. 2019 Dec 3. doi: 10.1007/s10067-019-04821-w. [Epub ahead of print]

PMID:
31797167
2.

Cervical Spine Involvement is very rare in Patients with Rheumatoid Arthritis Treated actively with Treat to Target Strategy. Ten-Year Results of the NEORACo Study.

Sandström T, Rantalaiho V, Yli-Kerttula T, Kautiainen H, Malmi T, Karjalainen A, Uusitalo T, Julkunen H, Kaipiainen-Seppänen O, Paimela L, Puolakka K, Uutela T, Möttönen T, Hannonen P, Leirisalo-Repo M, Laasonen L, Kauppi M; NEO-RACo Study Group.

J Rheumatol. 2019 Nov 15. pii: jrheum.190139. doi: 10.3899/jrheum.190139. [Epub ahead of print]

PMID:
31732558
3.

Effectiveness of psychosocial interventions on quality of life of patients with schizophrenia and related disorders: A systematic review.

Puolakka K, Pitkänen A.

Arch Psychiatr Nurs. 2019 Oct;33(5):73-82. doi: 10.1016/j.apnu.2019.07.001. Epub 2019 Jul 4.

PMID:
31711598
4.

Opioid use among 12 115 patients with early inflammatory arthritides compared to general population.

Muilu P, Rantalaiho V, Kautiainen H, Virta LJ, Puolakka K.

J Rheumatol. 2019 Oct 15. pii: jrheum.190355. doi: 10.3899/jrheum.190355. [Epub ahead of print]

PMID:
31615910
5.

Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries.

Putrik P, Ramiro S, Guillemin F, Péntek M, Sivera F, Sokka T, de Wit M, Woolf AD, Zink A, Andersone D, Berghea F, Butrimiene I, Brouwer S, Cassar K, Charalambous P, Caporali R, Deseatnicova E, Damjanov NS, Finckh A, FitzGerald O, Gröndal G, Gobejishjvili N, Gluszko P, Hirsch M, Jovanovic I, Vencovský J, Janssens X, Keszei AP, Kovarova M, Kull M, Cunha Miranda L, Mayer M, Misevska-Percinkova S, Inanc N, Nadashkevich O, Petersson IF, Puolakka K, Rojkovich B, Radner H, Szabados F, Slobodin G, Shirinsky I, Soroka N, Sidiropoulos P, Shumnalieva R, Sokolovic S, Shukurova S, Tafaj A, Tomšič M, Uhlig T, Verstappen SMM, Boonen A.

Ann Rheum Dis. 2019 Nov;78(11):1472-1479. doi: 10.1136/annrheumdis-2019-215294. Epub 2019 Aug 19.

PMID:
31427438
6.

Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis.

Pohjankoski H, Kautiainen H, Lauri JV, Puolakka K, Rantalaiho V.

Clin Rheumatol. 2019 Nov 16. doi: 10.1007/s10067-019-04702-2. [Epub ahead of print] Erratum in: Clin Rheumatol. 2019 Dec 3;:.

PMID:
31346886
7.

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.

Huoponen S, Aaltonen KJ, Viikinkoski J, Rutanen J, Relas H, Taimen K, Puolakka K, Nordström D, Blom M.

PLoS One. 2019 Jul 24;14(7):e0220142. doi: 10.1371/journal.pone.0220142. eCollection 2019.

8.

Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland.

Purmonen T, Puolakka K, Mishra D, Gunda P, Martikainen J.

Clinicoecon Outcomes Res. 2019 Feb 15;11:159-168. doi: 10.2147/CEOR.S192235. eCollection 2019.

9.

The mortality rate and causes of death among juvenile idiopathic arthritis patients in Finland.

Kyllönen MS, Kautiainen H, Puolakka K, Vähäsalo P.

Clin Exp Rheumatol. 2019 May-Jun;37(3):508-511. Epub 2019 Feb 11.

PMID:
30767877
10.

Automated text message enhanced monitoring versus routine monitoring in early rheumatoid arthritis: a randomized trial.

Kuusalo L, Sokka-Isler T, Kautiainen H, Ekman P, Kauppi MJ, Pirilä L, Rannio T, Uutela T, Yli-Kerttula T, Puolakka K; SandRA Study Group.

Arthritis Care Res (Hoboken). 2019 Feb 11. doi: 10.1002/acr.23846. [Epub ahead of print]

PMID:
30740935
11.

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.

Purmonen T, Puolakka K, Bhattacharyya D, Jain M, Martikainen J.

Cost Eff Resour Alloc. 2018 Nov 16;16:56. doi: 10.1186/s12962-018-0162-3. eCollection 2018.

12.

Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis.

Purmonen T, Törmälehto S, Wahlman H, Puolakka K.

J Med Econ. 2019 Feb;22(2):151-157. doi: 10.1080/13696998.2018.1551227. Epub 2018 Dec 4.

PMID:
30474450
13.

Increasing incidence and shifting profile of idiopathic inflammatory rheumatic diseases in adults during this millennium.

Muilu P, Rantalaiho V, Kautiainen H, Virta LJ, Eriksson JG, Puolakka K.

Clin Rheumatol. 2019 Feb;38(2):555-562. doi: 10.1007/s10067-018-4310-0. Epub 2018 Sep 26.

PMID:
30259249
14.

Impact of early systemic lupus erythematosus on work disability-results from the Finnish nationwide register 2000-2007.

Elfving P, Puolakka K, Rantalaiho V, Kautiainen H, Virta LJ, Kaipiainen-Seppänen O.

Clin Rheumatol. 2018 May;37(5):1413-1416. doi: 10.1007/s10067-018-4066-6. Epub 2018 Mar 14.

PMID:
29541950
15.

High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis.

Kuusalo L, Puolakka K, Kautiainen H, Karjalainen A, Malmi T, Paimela L, Leirisalo-Repo M, Rantalaiho V; NEO-RACo Study Group.

Clin Rheumatol. 2018 Jun;37(6):1689-1694. doi: 10.1007/s10067-017-3958-1. Epub 2017 Dec 26.

PMID:
29280011
16.

Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.

Soini E, Asseburg C, Taiha M, Puolakka K, Purcaru O, Luosujärvi R.

Adv Ther. 2017 Oct;34(10):2316-2332. doi: 10.1007/s12325-017-0614-8. Epub 2017 Oct 3.

17.

Alternative interpretation of data for recommendations on how to manage rheumatoid arthritis.

Pirilä L, Sokka T, Kauppi MJ, Rantalaiho VM, Mervaala E, Puolakka K.

Ann Rheum Dis. 2017 Dec;76(12):e49. doi: 10.1136/annrheumdis-2017-211505. Epub 2017 Apr 27. No abstract available.

PMID:
28450311
18.

Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach.

Kuusalo L, Puolakka K, Kautiainen H, Karjalainen A, Malmi T, Yli-Kerttula T, Leirisalo-Repo M, Rantalaiho V; NEO-RACo Study Group.

Rheumatol Int. 2017 May;37(5):825-830. doi: 10.1007/s00296-017-3692-7. Epub 2017 Mar 13.

PMID:
28289873
19.

Profile of initial drug therapy in paediatric systemic lupus erythematosus in Finland, 2000-2007.

Elfving P, Puolakka K, Kautiainen H, Virta LJ, Pohjolainen T, Kaipiainen-Seppänen O.

Clin Exp Rheumatol. 2017 Mar-Apr;35(2):352. Epub 2017 Jan 15. No abstract available.

PMID:
28094755
20.

Improving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic tools.

van Riel P, Alten R, Combe B, Abdulganieva D, Bousquet P, Courtenay M, Curiale C, Gómez-Centeno A, Haugeberg G, Leeb B, Puolakka K, Ravelli A, Rintelen B, Sarzi-Puttini P.

RMD Open. 2016 Nov 24;2(2):e000302. eCollection 2016. Review.

21.

Longterm Work Productivity Costs Due to Absenteeism and Permanent Work Disability in Patients with Early Rheumatoid Arthritis: A Nationwide Register Study of 7831 Patients.

Martikainen JA, Kautiainen H, Rantalaiho V, Puolakka KT.

J Rheumatol. 2016 Dec;43(12):2101-2105. Epub 2016 Oct 1.

PMID:
27909140
22.

Intra-articular glucocorticoid injections should not be neglected in the remission targeted treatment of early rheumatoid arthritis: a post hoc analysis from the NEO-RACo trial.

Kuusalo LA, Puolakka KT, Kautiainen H, Alasaarela EM, Hannonen PJ, Julkunen HA, Kaipiainen-Seppänen OA, Korpela MM, Möttönen TT, Paimela LH, Peltomaa RL, Yli-Kerttula TK, Leirisalo-Repo M, Rantalaiho VM; NEO-RACo Study Group.

Clin Exp Rheumatol. 2016 Nov-Dec;34(6):1038-1044. Epub 2016 Aug 2.

PMID:
27494516
23.

Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.

Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M.

Rheumatology (Oxford). 2016 Oct;55(10):1803-11. doi: 10.1093/rheumatology/kew264. Epub 2016 Jun 27.

PMID:
27354689
24.

A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs.

Aaltonen KJ, Turunen JH, Sokka T, Puolakka K, Valleala H.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):694-7. Epub 2016 May 19.

PMID:
27213997
25.

Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers.

Laine J, Jokiranta TS, Eklund KK, Väkeväinen M, Puolakka K.

Biologics. 2016 Apr 1;10:67-73. doi: 10.2147/BTT.S96982. eCollection 2016.

26.

Improving data collection processes for routine evaluation of treatment cost-effectiveness.

Monto S, Penttilä R, Kärri T, Puolakka K, Valpas A, Talonpoika AM.

Health Inf Manag. 2016 Apr;45(1):45-52. doi: 10.1177/1833358316639451.

PMID:
28691566
27.

Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007.

Elfving P, Puolakka K, Kautiainen H, Virta LJ, Pohjolainen T, Kaipiainen-Seppänen O.

Lupus. 2016 May;25(6):666-70. doi: 10.1177/0961203316628998. Epub 2016 Jan 27.

PMID:
26821964
28.

Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial.

Kuusalo L, Puolakka K, Kautiainen H, Blåfield H, Eklund KK, Ilva K, Kaipiainen-Seppänen O, Karjalainen A, Korpela M, Valleala H, Leirisalo-Repo M, Rantalaiho V; Neo-RACo Study Group.

Scand J Rheumatol. 2015;44(6):449-55. doi: 10.3109/03009742.2015.1043142. Epub 2015 Aug 31.

PMID:
26324784
29.

No increased cardiovascular mortality among early rheumatoid arthritis patients: a nationwide register study in 2000-2008.

Kerola AM, Nieminen TV, Virta LJ, Kautiainen H, Kerola T, Pohjolainen T, Kauppi MJ, Puolakka K.

Clin Exp Rheumatol. 2015 May-Jun;33(3):391-8. Epub 2015 May 1.

PMID:
25936374
30.

Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.

Aaltonen KJ, Joensuu JT, Virkki L, Sokka T, Aronen P, Relas H, Valleala H, Rantalaiho V, Pirilä L, Puolakka K, Uusitalo T, Blom M, Konttinen YT, Nordström D.

J Rheumatol. 2015 Mar;42(3):372-8. doi: 10.3899/jrheum.140853. Epub 2015 Jan 15.

PMID:
25593230
31.

Mental Health Promotion in School: Schoolchildren's and Families' Viewpoint.

Puolakka K, Konu A, Kiikkala I, Paavilainen E.

Nurs Res Pract. 2014;2014:395286. doi: 10.1155/2014/395286. Epub 2014 Nov 19.

32.

Long-Term Work Productivity Costs Among Subjects With Early Rheumatoid Arthritis - A Nationwide Analysis Based on 7,831 Subjects' Sickness Absence Days and Income.

Martikainen JA, Krol M, Rantalaiho V, Kautiainen H, Puolakka K.

Value Health. 2014 Nov;17(7):A383. doi: 10.1016/j.jval.2014.08.2628. Epub 2014 Oct 26. No abstract available.

33.

Psychiatric and cardiovascular comorbidities as causes of long-term work disability among individuals with recent-onset rheumatoid arthritis.

Kerola AM, Kauppi MJ, Nieminen T, Rantalaiho V, Kautiainen H, Kerola T, Virta LJ, Pohjolainen T, Puolakka K.

Scand J Rheumatol. 2015;44(2):87-92. doi: 10.3109/03009742.2014.929174. Epub 2014 Oct 29.

PMID:
25352417
34.

Incidence of systemic lupus erythematosus in Finland, 2000-2007, a nationwide study.

Elfving P, Puolakka K, Kautiainen H, Virta LJ, Pohjolainen T, Kaipiainen-Seppänen O.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):953-5. Epub 2014 Oct 20.

PMID:
25328038
35.

Mortality and causes of death among incident cases of systemic lupus erythematosus in Finland 2000-2008.

Elfving P, Puolakka K, Kautiainen H, Virta LJ, Pohjolainen T, Kaipiainen-Seppänen O.

Lupus. 2014 Nov;23(13):1430-4. doi: 10.1177/0961203314543919. Epub 2014 Jul 23.

PMID:
25057036
36.

Increased risk of levothyroxine-treated hypothyroidism preceding the diagnosis of rheumatoid arthritis: a nationwide registry study.

Kerola AM, Nieminen TV, Kauppi MJ, Kautiainen H, Puolakka K, Virta LJ, Kerola T.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4):455-9. Epub 2014 Jun 6.

PMID:
24959977
37.

Survival of disease-modifying antirheumatic drugs used as the first antirheumatic medication in the treatment of ankylosing spondylitis in Finland. A nationwide population-based register study.

Relas H, Kautiainen H, Puolakka K, Virta LJ, Leirisalo-Repo M.

Clin Rheumatol. 2014 Aug;33(8):1135-8. doi: 10.1007/s10067-014-2700-5. Epub 2014 Jun 7.

PMID:
24907035
38.

Antidepressant use among persons with recent-onset rheumatoid arthritis: a nationwide register-based study in Finland.

Jyrkkä J, Kautiainen H, Koponen H, Puolakka K, Virta LJ, Pohjolainen T, Lönnroos E.

Scand J Rheumatol. 2014;43(5):364-70. doi: 10.3109/03009742.2013.878386. Epub 2014 Mar 21.

PMID:
24650284
39.

Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial.

Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Blåfield H, Ilva K, Hannonen P, Leirisalo-Repo M, Möttönen T; FIN-RACo Study Group.

Ann Rheum Dis. 2014 Apr;73(4):788-90. doi: 10.1136/annrheumdis-2013-204271. Epub 2013 Dec 2. No abstract available.

PMID:
24297374
40.

Using grounded theory to create a substantive theory of promoting schoolchildren's mental health.

Puolakka K, Haapasalo-Pesu KM, Kiikkala I, Astedt-Kurki P, Paavilainen E.

Nurse Res. 2013 Jan;20(3):22-7.

PMID:
23346775
41.

Cardiovascular comorbidities antedating the diagnosis of rheumatoid arthritis.

Kerola AM, Kerola T, Kauppi MJ, Kautiainen H, Virta LJ, Puolakka K, Nieminen TV.

Ann Rheum Dis. 2013 Nov;72(11):1826-9. doi: 10.1136/annrheumdis-2012-202398. Epub 2012 Nov 23.

PMID:
23178207
42.

Mental health promotion in a school community by using the results from the Well-being Profile: an action research project.

Puolakka K, Haapasalo-Pesu KM, Konu A, Astedt-Kurki P, Paavilainen E.

Health Promot Pract. 2014 Jan;15(1):44-54. doi: 10.1177/1524839912464876. Epub 2012 Nov 19.

PMID:
23171651
43.

Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis.

Rantalaiho V, Puolakka K, Korpela M, Hannonen P, Möttönen T.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S27-31. Epub 2012 Oct 16.

PMID:
23073350
44.

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

Leirisalo-Repo M, Kautiainen H, Laasonen L, Korpela M, Kauppi MJ, Kaipiainen-Seppänen O, Luosujärvi R, Luukkainen R, Karjalainen A, Blåfield H, Uutela T, Ilva K, Julkunen HA, Paimela L, Puolakka K, Moilanen E, Hannonen PJ, Möttönen T; NEO-RACo Study Group.

Ann Rheum Dis. 2013 Jun;72(6):851-7. doi: 10.1136/annrheumdis-2012-201365. Epub 2012 Jun 30.

PMID:
22753402
45.

Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish register, 2000-8.

Rantalaiho VM, Kautiainen H, Järvenpää S, Virta L, Pohjolainen T, Korpela M, Möttönen T, Puolakka K.

Ann Rheum Dis. 2013 May;72(5):672-7. doi: 10.1136/annrheumdis-2011-200701. Epub 2012 Jun 7.

PMID:
22679306
46.

Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland.

Puolakka K, Blåfield H, Kauppi M, Luosujärvi R, Peltomaa R, Leikola-Pelho T, Sennfalt K, Beresniak A.

Open Rheumatol J. 2012;6:38-43. doi: 10.2174/1874312901206010038. Epub 2012 Apr 26.

47.

Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.

Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ.

J Med Econ. 2012;15(2):340-51. doi: 10.3111/13696998.2011.649327. Epub 2012 Jan 6.

PMID:
22168785
48.

First-year purchases of disease-modifying drugs of incident patients with chronic juvenile arthritis in Finland.

Pohjankoski H, Latva K, Kautiainen H, Säilä H, Klaukka T, Virta L, Puolakka K, Pohjolainen T, Savolainen A.

Clin Exp Rheumatol. 2011 Sep-Oct;29(5):878-81. Epub 2011 Oct 31.

PMID:
21961808
49.

Use of osteoporosis drugs in patients with recent-onset rheumatoid arthritis in Finland.

Hämäläinen H, Kautiainen H, Pohjolainen T, Virta L, Järvenpää S, Puolakka K.

Clin Exp Rheumatol. 2011 Sep-Oct;29(5):835-8. Epub 2011 Oct 31.

PMID:
21961794
50.

Trends in treatment strategies and the usage of different disease-modifying anti-rheumatic drugs in early rheumatoid arthritis in Finland. Results from a nationwide register in 2000-2007.

Rantalaiho V, Kautiainen H, Virta L, Korpela M, Möttönen T, Puolakka K.

Scand J Rheumatol. 2011 Jan;40(1):16-21. doi: 10.3109/03009742.2010.486768. Epub 2010 Aug 20.

PMID:
20726683

Supplemental Content

Loading ...
Support Center